Shots:  

• The approval is based on P-lll IMbrave150 study assessing Tecentriq (1200mg) and Avastin (100 mg/4 mL and 400 mg/16 mL) vs sorafenib in 501 patients in a ratio (2:1) with HCC- prior not treated with systemic therapy
• Result of IMbrave150 study: Reduction in risk of death (42%)- reduction in the risk of disease worsening (41%)- published in NEJM
• The dual regimen has received the MHLW’s PR based on the positive data showing improvement of prognosis- subsequently led to the approval seven months after the filing of the application

­ Ref:  Roche | Image: Chugai